<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643212</url>
  </required_header>
  <id_info>
    <org_study_id>2014-005523-27</org_study_id>
    <nct_id>NCT02643212</nct_id>
  </id_info>
  <brief_title>Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis</brief_title>
  <acronym>CIRROXABAN</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>David Garcia Cinca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IDIBAPS - Dr. Juan Carlos García Pagán</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study will determine if patients with liver cirrhosis,
      anticoagulation free survival improves hypertension decompensation portal and / or
      transplantation without serious side effects. For it is conduct a double-blind multicenter
      clinical trial in which patients will be randomized to receive Rivaroxaban or placebo. It
      included 160 patients with liver cirrhosis and insufficiency mild to moderate hepatic. It
      will also analyze and develop secondary endpoint portal vein thrombosis. The confirmation of
      our hypothesis would lead to a radical change in treatment of patients with cirrhosis include
      treatment with Rivaroxaban in its drove.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival free of transplant and decompensation / complications of portal hypertension.</measure>
    <time_frame>At month 24</time_frame>
    <description>Is defined as decompensation / complications of portal hypertension:
significant bleeding episode (defined as Baveno V) by portal hypertension (esophageal varices, gastric varices; gastropathy Portal Hypertension)
Hepatic encephalopathy grade II or higher.
decompensation of ascites: In patients without ascites decompensation be considered the onset of clinically detectable ascites and confirmed by utrasounds de novo; whereas in those with previous ascites will be considered end-point for worsening ascites if required: a) perform two or more paracentesis evacuator in the next 6 months, or b) the completion of a Transjugular intrahepatic portosystemic shunt.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cirrhosis progression disease (bleeding episode, encephalopathy, ascitis)</measure>
    <time_frame>At month 24</time_frame>
    <description>Bleeding episode due to portal hypertension.
Hepatic encephalopathy grade II or higher.
Ascitic decompensation: In patients without ascites, decompensation defined as &quot;de novo&quot; clinically detectable ascites; whereas in those with previous ascites is considered end-point for worsening ascites if required: a) perform two or more evacuative paracentesis in the following six months, or b) the completion of a TIPS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of portal vein thrombosis detected by ultrasound and confirmed by CT angiography or MRI angiography</measure>
    <time_frame>At month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy in preventing complications of portal hypertension</measure>
    <time_frame>At month 24</time_frame>
    <description>Development of complications of portal hypertension (anamnesis, physical examination, ultrasound and fibrogastroscopy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Security of rivaroxaban in patients with liver cirrhosis, number of adverse events and adverse reactions in each arm of study. History and clinical evaluation of bleeding and monitoring of hematocrit. Evaluation of liver function</measure>
    <time_frame>At month 24</time_frame>
    <description>Evaluate number of bleeding episodes, hematocrit values and number of adverse events and reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence of hepatocellular carcinoma</measure>
    <time_frame>At month 24</time_frame>
    <description>Incidence of hepatocellular carcinoma by semiannual ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on splenic and liver elasticity measured by fibroscan and / or acoustic radiation force impulse.</measure>
    <time_frame>At month 24</time_frame>
    <description>Effect of rivaroxaban on liver fibrosis assessed by liver elastography measured by fibroscan and / or acoustic radiation force impulse at baseline and every six months conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Rivaroxaban on hepatocellular function estimated by the Child-Pugh and the model for end-stage liver disease scores.</measure>
    <time_frame>At month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To correlate levels of anti-factor Xa and Rivaroxaban on survival free of transplant, cirrhosis progression disease (bleeding episode, encephalopathy, ascitis) and number of adverse events and reactions.</measure>
    <time_frame>At month 24</time_frame>
    <description>To correlate levels of Rivaroxaban and anti-factor Xa to the efficacy and safety of the drug. Rivaroxaban</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of Rivaroxaban on hepatic venous pressure gradient</measure>
    <time_frame>At month 24</time_frame>
    <description>Effect on hepatic venous pressure gradient. Determination of hepatic venous pressure gradient at baseline and 12 months rivaroxaban or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess if Rivaroxaban reduces concentration of intestinal fatty acid binding protein, 16S ribosomal DNA, CD14, interleukin 6, lipopolysaccharide binding protein and lipopolysaccharide</measure>
    <time_frame>At month 24</time_frame>
    <description>Assess Rivaroxaban reduces bacterial translocation and proinflammatory cytokines. Correlation with clinical events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 10mg, 1 once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 18 and 75 years of both sexes.

          -  Clinical and / or laboratory criteria, ultrasound and / or liver biopsy compatible
             with the diagnosis of viral cirrhosis (If hepatitis B virus: hepatitis B virus-DNA
             must be negative; if hepatitis C virus: sustained virologic response should be at
             least for 6 months prior to enrollment); alcohol (in the last 6 months: in men less
             than 60 g daily intake in women less than 40 g); nonalcoholic steatohepatitis and
             cryptogenic.

          -  Presence of clinically significant portal hypertension defined by clinical criteria
             (presence of esophageal varices or ascites), elastography (liver Fibroscan® ? 21 kPa)
             or hemodynamic (Hepatic venous pressure gradient &gt; 10 mmHg)

          -  Mild to moderate hepatic impairment defined by Child-Pugh of 7-10 points.

          -  Written informed consent to participate in the study

        Exclusion Criteria:

          -  Any previous or current thrombosis in splenoportal axis (must be ruled out by
             US-Doppler earlier than one month after randomization; if doubts: computed tomography
             angiography or magnetic resonance angiography if required).

          -  Background of hepatic encephalopathy grade II or higher

          -  Ascites that required prior practice of paracentesis in the last year d. Indication
             for use of anticoagulant and / or antiplatelet therapy for any reason.

          -  Hypersensitivity to the active ingredient or to excipients

          -  Active bleeding, clinically significant, or risk of major bleeding.

          -  Pregnancy and lactation.

          -  Hepatocellular carcinoma or malignant neoplasia at the time of inclusion.

          -  Any comorbidity involving a therapeutic limitation and/or a life expectancy &lt;12
             months.

          -  Existence of risk bleeding esophageal varices or prior variceal bleeding. They may not
             be included until full treatment (stable beta blockers dosage or eradication trough
             varices ligation).

          -  Pregnancy or lactation.

          -  Severe thrombocytopenia &lt;40,000 platelets / dl.

          -  Kidney failure (creatinine clearance &lt;15ml / min).

          -  Transjugular intrahepatic portosystemic shunt or portosystemic shunt carrier.

          -  Child-Pugh score greater than 10.

          -  In hepatitis C virus liver cirrhosis patients: not carrying at least six months in
             sustained virologic response. In hepatitis B virus liver cirrhosis patients: hepatitis
             B virus DNA is not negative .

          -  Active alcoholism (60 g / day in men and 40 in women)

          -  Use of potent inhibitors of cytochrome cytochrome P450 3A4 (ketoconazole, protease
             inhibitor antiretroviral treatment in human immunodeficiency virus patients) or
             cytochrome inductors (rifampicin. Phenytoin ...).

          -  Participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juan Carlos García Pagan, MD</last_name>
    <phone>+34 93 227 54 00</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Garcia Cinca</last_name>
    <phone>+34 93 227 54 00</phone>
    <email>dgarcia@clinic.ub.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carmen Alvarez-Navascués</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital German Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Betty Paola Morales</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José Castellote</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angela Puente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro de Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>José Luis Calleja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau.</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Càndid Villanueva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d´Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Joan Genescà</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan Carlos Garcia-Pagan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lérida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carles Aracil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rafael Bañares</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Agustin Albillos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra_Hospital Montecelo</name>
      <address>
        <city>Pontevedra</city>
        <zip>36471</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan Turnes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Tenerife</name>
      <address>
        <city>Tenerife</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Manuel Hernández-Guerra de Aguilar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital universitari i politècnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>María Berenguer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>David Garcia Cinca</investigator_full_name>
    <investigator_title>Project Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

